Post-Traumatic Stress Disorder Therapeutics Market Report 2024: Size, Share, Growth, Forecast 2033

"The new report published by The Business Research Company, titled ""Post-Traumatic Stress Disorder Therapeutics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the post-traumatic stress disorder therapeutics market size has grown strongly in recent years. It will grow from $1.09 billion in 2023 to $1.15 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.35 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9214&type=smp

Surge In Ptsd Cases Drives Growth In Therapeutics Market
The rise in the burden of post-traumatic stress disorder (PTSD) cases across the globe are expected to propel the growth of the post-traumatic stress disorder therapeutics market going forward. Post-traumatic stress disorder refers to a disorder that develops in people who have experienced a scary, shocking, or dangerous event. Post-traumatic stress disorder treatment such as psychotherapy and medication can help to regain a sense of control over their life. For instance, according to the United States Department of Veterans Affairs, a US-based government department, nearly 8 million Americans are suffering from PTSD condition in 2021. Hence the rise in the burden of post-traumatic stress disorder (PTSD) cases is driving the growth of the post-traumatic stress disorder therapeutics market.

Collaborations And Investments Drive Innovation In Ptsd Therapeutics Market
Strategic collaborations, funding, and investments have emerged as a key trend gaining popularity in the post-traumatic stress disorder therapeutics market. Major companies operating in the market are developing strategic collaborations and investing in the companies to strengthen their position in the market. For instance, in January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University, members of an interdisciplinary research team were given over $1.9 million to study the effectiveness of MDMA-assisted psychological treatment for treating alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD). The initiative is one of seven clinical studies under the Medical Research Future Fund (MRFF) unveiled this month by the Federal government to evaluate the use of potentially ground-breaking combination medicines to treat crippling mental diseases.

The post-traumatic stress disorder therapeutics market covered in this report is segmented -
1) By Drug Class: Antidepressants, Anti-Anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics Or Second Generation Antipsychotics (SGOs), Beta-Blockers, Other Classes
2) By Age Group: Pediartic, Geriatric, Adult
3) By End User: Mental Health Center, Hospitals, Outpaitent Clinics, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9214&type=discount

Major companies operating in the post-traumatic stress disorder therapeutics market report are Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Bionomics Limited, Apotex Inc., Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, Behavioral Health Network Inc., AstraZeneca plc, Prometheon Pharma LLC, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Addex Therapeutics Ltd., Stella Center, Neurovation Labs Inc., Equip Global Pte Ltd., Compass Pathways plc, Boehringer Ingelheim International GmbH, Halucenex Life Sciences Inc., Bionorica SE, MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., Biogen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Industries Limited, Strategic Behavioral Health, Jazz Pharmaceuticals plc .

Contents of the report:
1. Executive Summary
2. Post-Traumatic Stress Disorder Therapeutics Market Report Structure
3. Post-Traumatic Stress Disorder Therapeutics Market Trends And Strategies
4. Post-Traumatic Stress Disorder Therapeutics Market - Macro Economic Scenario
5. Post-Traumatic Stress Disorder Therapeutics Market Size And Growth
…..
27. Post-Traumatic Stress Disorder Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/post-traumatic-stress-disorder-therapeutics-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.